Telomir Pharmaceuticals Inc. (Nasdaq: TELO) has announced its participation in the upcoming BIO International Convention 2025 in Boston, Massachusetts, scheduled from June 16-19, 2025. The company plans to engage in BIO One-on-One Partnering™ meetings to explore potential licensing, strategic collaborations, and M&A opportunities. Additionally, Telomir provided updates on its lead candidate, Telomir-1, which is designed to elongate telomeres, regenerate cells, and address key drivers of biological aging. The company is preparing for an Investigational New Drug $(IND.AU)$ submission by the end of the year and anticipates initiating first-in-human clinical trials in the first half of 2026. Telomir also reported preclinical progress in areas such as retinal regeneration, lifespan extension, Type 2 diabetes reversal, and anti-cancer effects. Furthermore, Telomir is launching a rare disease development initiative targeting conditions like Werner's syndrome, Wilson's disease, Progeria, and dysphonia.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。